{"transactions":[{"id":2504296,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-11-18T22:54:29.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":3332,"price":17.1169,"value":57033.5108,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range."}],"balance_after":113097,"source":{"system":"sec-edgar","filing":"0001567619-21-020780","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921020780/doc1.xml","form_type":"4"}},{"id":2506305,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-11-17T21:15:44.000Z","date":"2021-11-15","kind":"exercise","acquired":false,"shares":708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":9917,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":708},"source":{"system":"sec-edgar","filing":"0001567619-21-020653","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921020653/doc1.xml","form_type":"4"}},{"id":2506304,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-11-17T21:15:44.000Z","date":"2021-11-15","kind":"exercise","acquired":false,"shares":2792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":32083,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":2792},"source":{"system":"sec-edgar","filing":"0001567619-21-020653","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921020653/doc1.xml","form_type":"4"}},{"id":2506303,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-11-17T21:15:44.000Z","date":"2021-11-15","kind":"sale","acquired":false,"shares":7000,"price":17.7149,"value":124004.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.62 to $17.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":116429,"source":{"system":"sec-edgar","filing":"0001567619-21-020653","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921020653/doc1.xml","form_type":"4"}},{"id":2506302,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-11-17T21:15:44.000Z","date":"2021-11-15","kind":"exercise","acquired":true,"shares":3500,"price":12.15,"value":42525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":123429,"source":{"system":"sec-edgar","filing":"0001567619-21-020653","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921020653/doc1.xml","form_type":"4"}},{"id":2559561,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-09-24T21:35:59.000Z","date":"2021-09-22","kind":"exercise","acquired":false,"shares":2125,"price":17,"value":36125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":10625,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001567619-21-017578","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921017578/doc1.xml","form_type":"4"}},{"id":2559560,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-09-24T21:35:59.000Z","date":"2021-09-22","kind":"exercise","acquired":false,"shares":8375,"price":17,"value":142375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":34875,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":8375},"source":{"system":"sec-edgar","filing":"0001567619-21-017578","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921017578/doc1.xml","form_type":"4"}},{"id":2559559,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-09-24T21:35:59.000Z","date":"2021-09-22","kind":"sale","acquired":false,"shares":10500,"price":17,"value":178500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":119929,"source":{"system":"sec-edgar","filing":"0001567619-21-017578","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921017578/doc1.xml","form_type":"4"}},{"id":2559558,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-09-24T21:35:59.000Z","date":"2021-09-22","kind":"exercise","acquired":true,"shares":10500,"price":12.15,"value":127575.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":130429,"source":{"system":"sec-edgar","filing":"0001567619-21-017578","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921017578/doc1.xml","form_type":"4"}},{"id":2564980,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-09-17T20:36:55.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":3116,"price":15.6121,"value":48647.3036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.54 to $15.73. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":119929,"source":{"system":"sec-edgar","filing":"0001567619-21-017260","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921017260/doc1.xml","form_type":"4"}},{"id":2584631,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-08-31T21:05:27.000Z","date":"2021-08-30","kind":"sale","acquired":false,"shares":3500,"price":15,"value":52500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":123045,"source":{"system":"sec-edgar","filing":"0001567619-21-016517","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921016517/doc1.xml","form_type":"4"}},{"id":2595886,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-08-19T23:36:36.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":2426,"price":12.532,"value":30402.632,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2021 and August 18, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":126545,"source":{"system":"sec-edgar","filing":"0001567619-21-016150","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921016150/doc1.xml","form_type":"4"}},{"id":2702485,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-05-20T20:33:37.000Z","date":"2021-05-18","kind":"sale","acquired":false,"shares":2453,"price":14.55,"value":35691.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":128971,"source":{"system":"sec-edgar","filing":"0001209191-21-034430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121034430/doc4.xml","form_type":"4"}},{"id":2709902,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-05-17T22:32:35.000Z","date":"2021-05-17","kind":"sale","acquired":false,"shares":3500,"price":15,"value":52500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":131424,"source":{"system":"sec-edgar","filing":"0001209191-21-033285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121033285/doc4.xml","form_type":"4"}},{"id":2753822,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-04-07T20:36:35.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":655,"price":14.74,"value":9654.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":134924,"source":{"system":"sec-edgar","filing":"0001209191-21-025888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121025888/doc4.xml","form_type":"4"}},{"id":2767553,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-03-30T21:18:48.000Z","date":"2021-03-26","kind":"sale","acquired":false,"shares":2640,"price":14.58,"value":38491.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.437 to $14.58. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":135579,"source":{"system":"sec-edgar","filing":"0001209191-21-023583","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121023583/doc4.xml","form_type":"4"}},{"id":2788727,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-15T23:25:44.000Z","date":"2021-03-15","kind":"exercise","acquired":false,"shares":709,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":12750,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":709},"source":{"system":"sec-edgar","filing":"0001209191-21-020578","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121020578/doc4.xml","form_type":"4"}},{"id":2788726,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-15T23:25:44.000Z","date":"2021-03-15","kind":"exercise","acquired":false,"shares":2791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":43250,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":2791},"source":{"system":"sec-edgar","filing":"0001209191-21-020578","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121020578/doc4.xml","form_type":"4"}},{"id":2788725,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-03-15T23:25:44.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":7000,"price":17.41,"value":121870.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.01 to $17.59. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":138219,"source":{"system":"sec-edgar","filing":"0001209191-21-020578","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121020578/doc4.xml","form_type":"4"}},{"id":2788724,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-03-15T23:25:44.000Z","date":"2021-03-15","kind":"exercise","acquired":true,"shares":3500,"price":12.15,"value":42525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":145219,"source":{"system":"sec-edgar","filing":"0001209191-21-020578","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121020578/doc4.xml","form_type":"4"}},{"id":2808078,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-03-04T21:08:14.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":1665,"price":16.74,"value":27872.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2021 and March 3, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":141719,"source":{"system":"sec-edgar","filing":"0001209191-21-017773","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121017773/doc4.xml","form_type":"4"}},{"id":2811301,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-03T22:15:38.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":56929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service."}],"balance_after":56929,"derivative":{"exercise_price":17.105,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":56929},"source":{"system":"sec-edgar","filing":"0001209191-21-017040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121017040/doc4.xml","form_type":"4"}},{"id":2811300,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-03-03T22:15:38.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":37715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service.  Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year."}],"balance_after":143384,"source":{"system":"sec-edgar","filing":"0001209191-21-017040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121017040/doc4.xml","form_type":"4"}},{"id":2871206,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-02-10T00:59:13.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":3886,"price":20.39,"value":79235.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 8, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":105669,"source":{"system":"sec-edgar","filing":"0001209191-21-009054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121009054/doc4.xml","form_type":"4"}},{"id":2903912,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-01-19T21:02:21.000Z","date":"2021-01-15","kind":"exercise","acquired":false,"shares":354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":13459,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":354},"source":{"system":"sec-edgar","filing":"0001209191-21-003996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121003996/doc4.xml","form_type":"4"}},{"id":2903911,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-01-19T21:02:21.000Z","date":"2021-01-15","kind":"exercise","acquired":false,"shares":3146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":46041,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":3146},"source":{"system":"sec-edgar","filing":"0001209191-21-003996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121003996/doc4.xml","form_type":"4"}},{"id":2903910,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-01-19T21:02:21.000Z","date":"2021-01-15","kind":"sale","acquired":false,"shares":7000,"price":18.84,"value":131880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.36 to $19.125. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":109555,"source":{"system":"sec-edgar","filing":"0001209191-21-003996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121003996/doc4.xml","form_type":"4"}},{"id":2903909,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2021-01-19T21:02:21.000Z","date":"2021-01-15","kind":"exercise","acquired":true,"shares":3500,"price":12.15,"value":42525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":116555,"source":{"system":"sec-edgar","filing":"0001209191-21-003996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121003996/doc4.xml","form_type":"4"}},{"id":2937302,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-18T23:35:35.000Z","date":"2020-12-16","kind":"exercise","acquired":false,"shares":354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":13813,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":354},"source":{"system":"sec-edgar","filing":"0001209191-20-064504","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120064504/doc4.xml","form_type":"4"}},{"id":2937301,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-18T23:35:35.000Z","date":"2020-12-16","kind":"exercise","acquired":false,"shares":3146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":49187,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":3146},"source":{"system":"sec-edgar","filing":"0001209191-20-064504","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120064504/doc4.xml","form_type":"4"}},{"id":2937300,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-12-18T23:35:35.000Z","date":"2020-12-16","kind":"sale","acquired":false,"shares":3500,"price":23.08,"value":80780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":113055,"source":{"system":"sec-edgar","filing":"0001209191-20-064504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120064504/doc4.xml","form_type":"4"}},{"id":2937299,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-12-18T23:35:35.000Z","date":"2020-12-16","kind":"sale","acquired":false,"shares":3500,"price":23.13,"value":80955.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":116555,"source":{"system":"sec-edgar","filing":"0001209191-20-064504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120064504/doc4.xml","form_type":"4"}},{"id":2937298,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-12-18T23:35:35.000Z","date":"2020-12-16","kind":"exercise","acquired":true,"shares":3500,"price":12.15,"value":42525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":120055,"source":{"system":"sec-edgar","filing":"0001209191-20-064504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120064504/doc4.xml","form_type":"4"}},{"id":2937297,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-18T23:32:59.000Z","date":"2020-11-13","kind":"exercise","acquired":false,"shares":2833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":14167,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":2833},"source":{"system":"sec-edgar","filing":"0001209191-20-064501","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120064501/doc4a.xml","form_type":"4/A","original_submission_date":"2020-11-16"}},{"id":2937296,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-12-18T23:32:59.000Z","date":"2020-11-13","kind":"exercise","acquired":false,"shares":667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":52333,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":667},"source":{"system":"sec-edgar","filing":"0001209191-20-064501","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120064501/doc4a.xml","form_type":"4/A","original_submission_date":"2020-11-16"}},{"id":2974378,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-11-18T21:07:50.000Z","date":"2020-11-17","kind":"sale","acquired":false,"shares":1648,"price":19.774,"value":32587.552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":116555,"source":{"system":"sec-edgar","filing":"0001209191-20-059046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120059046/doc4.xml","form_type":"4"}},{"id":2979361,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-11-16T21:19:34.000Z","date":"2020-11-13","kind":"exercise","acquired":false,"shares":667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":16333,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":667},"source":{"system":"sec-edgar","filing":"0001209191-20-058464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120058464/doc4.xml","form_type":"4"}},{"id":2979360,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-11-16T21:19:34.000Z","date":"2020-11-13","kind":"exercise","acquired":false,"shares":2833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":50167,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":2833},"source":{"system":"sec-edgar","filing":"0001209191-20-058464","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120058464/doc4.xml","form_type":"4"}},{"id":2979359,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-11-16T21:19:34.000Z","date":"2020-11-13","kind":"sale","acquired":false,"shares":1300,"price":19.12,"value":24856.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.85 to $19.18. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":118203,"source":{"system":"sec-edgar","filing":"0001209191-20-058464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120058464/doc4.xml","form_type":"4"}},{"id":2979358,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-11-16T21:19:34.000Z","date":"2020-11-13","kind":"sale","acquired":false,"shares":6200,"price":18.36,"value":113832.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.84 to $18.74. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":119503,"source":{"system":"sec-edgar","filing":"0001209191-20-058464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120058464/doc4.xml","form_type":"4"}},{"id":2979357,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-11-16T21:19:34.000Z","date":"2020-11-13","kind":"exercise","acquired":true,"shares":3500,"price":12.15,"value":42525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020."}],"balance_after":125703,"source":{"system":"sec-edgar","filing":"0001209191-20-058464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120058464/doc4.xml","form_type":"4"}},{"id":3050697,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-08-20T23:37:38.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":1678,"price":12.09,"value":20287.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2020 and August\n19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":122203,"source":{"system":"sec-edgar","filing":"0001209191-20-047819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120047819/doc4.xml","form_type":"4"}},{"id":3140360,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-05-20T22:11:53.000Z","date":"2020-05-18","kind":"sale","acquired":false,"shares":1603,"price":11.22,"value":17985.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2020 and May\n19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":123881,"source":{"system":"sec-edgar","filing":"0001209191-20-031007","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120031007/doc4.xml","form_type":"4"}},{"id":3180223,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-04-07T20:21:06.000Z","date":"2020-04-06","kind":"sale","acquired":false,"shares":657,"price":7.94,"value":5216.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":125484,"source":{"system":"sec-edgar","filing":"0001209191-20-023763","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120023763/doc4.xml","form_type":"4"}},{"id":3191923,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-03-30T20:05:56.000Z","date":"2020-03-27","kind":"sale","acquired":false,"shares":2740,"price":9.17,"value":25125.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":126141,"source":{"system":"sec-edgar","filing":"0001209191-20-021698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120021698/doc4.xml","form_type":"4"}},{"id":3230643,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-03T22:00:07.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":17000,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-20-015351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120015351/doc4.xml","form_type":"4"}},{"id":3230642,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-03T22:00:07.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":53000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service."}],"balance_after":53000,"derivative":{"exercise_price":12.15,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":53000},"source":{"system":"sec-edgar","filing":"0001209191-20-015351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120015351/doc4.xml","form_type":"4"}},{"id":3230641,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operations Officer"}}],"security":"Common Stock","published_at":"2020-03-03T22:00:07.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2020, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year."}],"balance_after":128881,"source":{"system":"sec-edgar","filing":"0001209191-20-015351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120015351/doc4.xml","form_type":"4"}},{"id":3281575,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2020-02-11T00:48:36.000Z","date":"2020-02-06","kind":"sale","acquired":false,"shares":4117,"price":14.21,"value":58502.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":53881,"source":{"system":"sec-edgar","filing":"0001209191-20-008126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120008126/doc4.xml","form_type":"4"}},{"id":3404167,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-09-30T20:25:35.000Z","date":"2019-09-27","kind":"sale","acquired":false,"shares":3500,"price":13.51,"value":47285.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.50 to $13.52. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":57998,"source":{"system":"sec-edgar","filing":"0001209191-19-051095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119051095/doc4.xml","form_type":"4"}},{"id":3536260,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-05-07T20:31:51.000Z","date":"2019-05-06","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":65000,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-19-027981","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119027981/doc4.xml","form_type":"4"}},{"id":3536259,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-05-07T20:31:51.000Z","date":"2019-05-06","kind":"sale","acquired":false,"shares":1500,"price":35,"value":52500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":61498,"source":{"system":"sec-edgar","filing":"0001209191-19-027981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119027981/doc4.xml","form_type":"4"}},{"id":3536258,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-05-07T20:31:51.000Z","date":"2019-05-06","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":62998,"source":{"system":"sec-edgar","filing":"0001209191-19-027981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119027981/doc4.xml","form_type":"4"}},{"id":3563666,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-04-03T23:22:28.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":66500,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-19-023491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119023491/doc4.xml","form_type":"4"}},{"id":3563665,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-04-03T23:22:28.000Z","date":"2019-04-03","kind":"tax_withholding","acquired":false,"shares":648,"price":41.04,"value":26593.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":61498,"source":{"system":"sec-edgar","filing":"0001209191-19-023491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119023491/doc4.xml","form_type":"4"}},{"id":3563664,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-04-03T23:22:28.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":1500,"price":39.96,"value":59940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.66 to $40.63. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":62146,"source":{"system":"sec-edgar","filing":"0001209191-19-023491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119023491/doc4.xml","form_type":"4"}},{"id":3563663,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-04-03T23:22:28.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":63646,"source":{"system":"sec-edgar","filing":"0001209191-19-023491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119023491/doc4.xml","form_type":"4"}},{"id":3571447,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-04-01T20:16:18.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":500,"price":38.44,"value":19220.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This amendment is being filed solely to correct the date of sale."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.31 to $38.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-19-021971","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119021971/doc4a.xml","form_type":"4/A","original_submission_date":"2019-02-01"}},{"id":3576206,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-03-27T21:18:14.000Z","date":"2019-03-26","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service."}],"balance_after":62146,"source":{"system":"sec-edgar","filing":"0001209191-19-021443","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119021443/doc4.xml","form_type":"4"}},{"id":3610518,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-05T23:58:31.000Z","date":"2019-03-01","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":68000,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-19-017038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119017038/doc4.xml","form_type":"4"}},{"id":3610517,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-03-05T23:58:31.000Z","date":"2019-03-01","kind":"sale","acquired":false,"shares":200,"price":36.75,"value":7350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.66 to $36.84. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":47146,"source":{"system":"sec-edgar","filing":"0001209191-19-017038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119017038/doc4.xml","form_type":"4"}},{"id":3610516,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-03-05T23:58:31.000Z","date":"2019-03-01","kind":"sale","acquired":false,"shares":1300,"price":36.04,"value":46852.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.56 to $36.43. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":47346,"source":{"system":"sec-edgar","filing":"0001209191-19-017038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119017038/doc4.xml","form_type":"4"}},{"id":3610515,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-03-05T23:58:31.000Z","date":"2019-03-01","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":48646,"source":{"system":"sec-edgar","filing":"0001209191-19-017038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119017038/doc4.xml","form_type":"4"}},{"id":3667580,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-08T21:22:31.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service."}],"balance_after":35000,"derivative":{"exercise_price":38.47,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-19-008504","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119008504/doc4.xml","form_type":"4"}},{"id":3667579,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-02-08T21:22:31.000Z","date":"2019-02-06","kind":"grant","acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject\nto the reporting person's continuous service."}],"balance_after":47146,"source":{"system":"sec-edgar","filing":"0001209191-19-008504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119008504/doc4.xml","form_type":"4"}},{"id":3667578,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-02-08T21:22:31.000Z","date":"2019-02-06","kind":"tax_withholding","acquired":false,"shares":2212,"price":38.47,"value":85095.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":29646,"source":{"system":"sec-edgar","filing":"0001209191-19-008504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119008504/doc4.xml","form_type":"4"}},{"id":3679282,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-01T23:49:08.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":69500,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-19-006607","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119006607/doc4.xml","form_type":"4"}},{"id":3679281,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-02-01T23:49:08.000Z","date":"2019-02-02","kind":"sale","acquired":false,"shares":500,"price":38.44,"value":19220.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.31 to $38.71. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-19-006607","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119006607/doc4.xml","form_type":"4"}},{"id":3679280,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-02-01T23:49:08.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":1000,"price":37.8,"value":37800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.28 to $38.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32358,"source":{"system":"sec-edgar","filing":"0001209191-19-006607","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119006607/doc4.xml","form_type":"4"}},{"id":3679279,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-02-01T23:49:08.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":33358,"source":{"system":"sec-edgar","filing":"0001209191-19-006607","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119006607/doc4.xml","form_type":"4"}},{"id":3712594,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-01-03T00:51:09.000Z","date":"2019-01-02","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":71000,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-19-000518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119000518/doc4.xml","form_type":"4"}},{"id":3712593,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-01-03T00:51:09.000Z","date":"2019-01-02","kind":"sale","acquired":false,"shares":1500,"price":35,"value":52500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-19-000518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119000518/doc4.xml","form_type":"4"}},{"id":3712592,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2019-01-03T00:51:09.000Z","date":"2019-01-02","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":33358,"source":{"system":"sec-edgar","filing":"0001209191-19-000518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919119000518/doc4.xml","form_type":"4"}},{"id":3745522,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-12-04T00:00:20.000Z","date":"2018-12-03","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":72500,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-18-060680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118060680/doc4.xml","form_type":"4"}},{"id":3745521,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-12-04T00:00:20.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":127,"price":42.54,"value":5402.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.49 to $42.66. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-18-060680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118060680/doc4.xml","form_type":"4"}},{"id":3745520,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-12-04T00:00:20.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":400,"price":41.97,"value":16788.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.40 to $42.38. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31985,"source":{"system":"sec-edgar","filing":"0001209191-18-060680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118060680/doc4.xml","form_type":"4"}},{"id":3745519,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-12-04T00:00:20.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":973,"price":40.61,"value":39513.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.30 to $41.28. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32385,"source":{"system":"sec-edgar","filing":"0001209191-18-060680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118060680/doc4.xml","form_type":"4"}},{"id":3745518,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-12-04T00:00:20.000Z","date":"2018-12-03","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":33358,"source":{"system":"sec-edgar","filing":"0001209191-18-060680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118060680/doc4.xml","form_type":"4"}},{"id":3775388,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-03T00:15:53.000Z","date":"2018-11-01","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":74000,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-18-057055","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118057055/doc4.xml","form_type":"4"}},{"id":3775387,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-11-03T00:15:53.000Z","date":"2018-11-01","kind":"sale","acquired":false,"shares":1500,"price":35,"value":52500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-18-057055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118057055/doc4.xml","form_type":"4"}},{"id":3775386,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-11-03T00:15:53.000Z","date":"2018-11-01","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":33358,"source":{"system":"sec-edgar","filing":"0001209191-18-057055","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118057055/doc4.xml","form_type":"4"}},{"id":3800553,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-10-02T20:25:31.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":75500,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-18-053131","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118053131/doc4.xml","form_type":"4"}},{"id":3800552,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-10-02T20:25:31.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":400,"price":41.99,"value":16796.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.75 to $42.21. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-18-053131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118053131/doc4.xml","form_type":"4"}},{"id":3800551,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-10-02T20:25:31.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":1100,"price":41.02,"value":45122.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.53 to $41.36. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32258,"source":{"system":"sec-edgar","filing":"0001209191-18-053131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118053131/doc4.xml","form_type":"4"}},{"id":3800550,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-10-02T20:25:31.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":33358,"source":{"system":"sec-edgar","filing":"0001209191-18-053131","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118053131/doc4.xml","form_type":"4"}},{"id":3824812,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-09-05T21:28:58.000Z","date":"2018-09-04","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":77000,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-18-049620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118049620/doc4.xml","form_type":"4"}},{"id":3824811,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-09-05T21:28:58.000Z","date":"2018-09-04","kind":"sale","acquired":false,"shares":498,"price":40.04,"value":19939.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.75 to $40.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-18-049620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118049620/doc4.xml","form_type":"4"}},{"id":3824810,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-09-05T21:28:58.000Z","date":"2018-09-04","kind":"sale","acquired":false,"shares":1002,"price":39.16,"value":39238.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.60 to $39.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32356,"source":{"system":"sec-edgar","filing":"0001209191-18-049620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118049620/doc4.xml","form_type":"4"}},{"id":3824809,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-09-05T21:28:58.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":33358,"source":{"system":"sec-edgar","filing":"0001209191-18-049620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118049620/doc4.xml","form_type":"4"}},{"id":3856452,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-08-01T22:21:06.000Z","date":"2018-08-01","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":78500,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-18-044804","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044804/doc4.xml","form_type":"4"}},{"id":3856451,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-08-01T22:21:06.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":100,"price":40.4,"value":4040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-18-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044804/doc4.xml","form_type":"4"}},{"id":3856450,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-08-01T22:21:06.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":300,"price":39.05,"value":11715.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.70 to $39.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31958,"source":{"system":"sec-edgar","filing":"0001209191-18-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044804/doc4.xml","form_type":"4"}},{"id":3856449,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-08-01T22:21:06.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":100,"price":37.65,"value":3765.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":32258,"source":{"system":"sec-edgar","filing":"0001209191-18-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044804/doc4.xml","form_type":"4"}},{"id":3856448,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-08-01T22:21:06.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":1000,"price":37.09,"value":37090.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.50 to $37.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":32358,"source":{"system":"sec-edgar","filing":"0001209191-18-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044804/doc4.xml","form_type":"4"}},{"id":3856447,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-08-01T22:21:06.000Z","date":"2018-08-01","kind":"exercise","acquired":true,"shares":1500,"price":20.4,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":33358,"source":{"system":"sec-edgar","filing":"0001209191-18-044804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044804/doc4.xml","form_type":"4"}},{"id":3857631,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-07-31T21:08:49.000Z","date":"2018-07-30","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service."}],"balance_after":80000,"derivative":{"exercise_price":20.4,"expiration_date":"2024-04-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-044584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044584/doc4.xml","form_type":"4"}},{"id":3857630,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-07-31T21:08:49.000Z","date":"2018-07-30","kind":"sale","acquired":false,"shares":1900,"price":36.37,"value":69103.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.20 to $36.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-18-044584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044584/doc4.xml","form_type":"4"}},{"id":3857629,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-07-31T21:08:49.000Z","date":"2018-07-30","kind":"sale","acquired":false,"shares":8100,"price":35.64,"value":288684.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.15 to $36.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":33758,"source":{"system":"sec-edgar","filing":"0001209191-18-044584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044584/doc4.xml","form_type":"4"}},{"id":3857628,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-07-31T21:08:49.000Z","date":"2018-07-30","kind":"exercise","acquired":true,"shares":10000,"price":20.4,"value":204000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018."}],"balance_after":41858,"source":{"system":"sec-edgar","filing":"0001209191-18-044584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118044584/doc4.xml","form_type":"4"}},{"id":3969031,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":133318,"kind":"person","name":"Newell Joe","position":1,"cik":"0001702457","reported_name":"Newell Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech. Operations Officer"}}],"security":"Common Stock","published_at":"2018-04-04T20:09:32.000Z","date":"2018-04-03","kind":"tax_withholding","acquired":false,"shares":642,"price":36.25,"value":23272.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":31858,"source":{"system":"sec-edgar","filing":"0001209191-18-023596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919118023596/doc4.xml","form_type":"4"}}],"next_cursor":"2018-04-04T20:09:32.000000Z,3969031"}